Is Moderna's Cancer Vaccine a Game Changer for the Stock?
The healthcare stock has hit multi-year highs this year amid positive results from its personalized cancer vaccine.
This year, Moderna (MRNA -3.63%) has seen its stock soar more than 600%, catapulting its market cap to near $90 billion. The excitement stems from the success of its cancer vaccine, intismeran, developed in collaboration with Merck. Recently, Moderna announced phase 3 clinical trial results showcasing the vaccine's effectiveness in treating melanoma patients when used alongside Merck's Keytruda.
The combined treatment proved to be more effective than Keytruda alone in reducing the risk of death and the spread or recurrence of cancer.
However, there are several factors to consider. While the stock's massive price movement suggests that investors may be pricing in the vaccine's potential to treat other cancers, this is not guaranteed. Producing a personalized cancer vaccine on a large scale can be both costly and time-consuming. Moreover, the profits generated from the treatment will be shared between Moderna and Merck, potentially limiting the long-term profits flowing to Moderna.
Despite the promising nature of intismeran, some investors might have overreacted, driving the stock's valuation beyond what is sustainable. The vaccine has yet to be approved for treating any cancer, and the market may be pricing it as if it could treat multiple malignancies. This premature enthusiasm could lead to investor disappointment if the stock's actual profitability falls short of expectations.
With these considerations in mind, the author advises against buying Moderna's stock at the current price point, suggesting that it may have peaked and could face considerable downside risk. The author also highlights the potential of Stock Advisor, which has delivered an impressive average return of 823% compared to the S&P 500's 209% over the same period.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.